| Drug General Information |
| Drug ID |
D0F8XK
|
| Former ID |
DPR000178
|
| Drug Name |
ISIS-GCCR
|
| Drug Type |
Antisense drug
|
| Indication |
Type 2 diabetes [ICD9: 250; ICD10:E11]
|
Preclinical |
[1]
|
|---|
| Company |
ISIS Pharm
|
| Target and Pathway |
| Target(s) |
mRNA of glucocorticoid receptor |
Target Info |
|
[1]
|
|---|
|
KEGG Pathway
|
Neuroactive ligand-receptor interaction
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
TCR Signaling Pathway
|
|
Pathway Interaction Database
|
Regulation of nuclear SMAD2/3 signaling
|
|
Signaling events mediated by HDAC Class II
|
|
FOXA2 and FOXA3 transcription factor networks
|
|
Glucocorticoid receptor regulatory network
|
|
Regulation of Androgen receptor activity
|
|
AP-1 transcription factor network
|
|
Reactome
|
BMAL1:CLOCK,NPAS2 activates circadian gene expression
|
|
WikiPathways
|
Serotonin Receptor 4/6/7 and NR3C Signaling
|
|
SIDS Susceptibility Pathways
|
|
Endoderm Differentiation
|
|
Hair Follicle Development: Cytodifferentiation (Part 3 of 3)
|
|
Adipogenesis
|
|
Circadian Clock
|
|
Nuclear Receptors
|
| References |
| REF 1 | Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011). |
|---|
